guanfacine has been researched along with Hemisensory Neglect in 3 studies
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirteen right hemisphere stroke patients with leftward neglect were included in a randomised, double-blind, placebo-controlled proof-of-concept crossover study that examined the effects of a single dose of guanfacine." | 9.27 | Randomised, double-blind, placebo-controlled crossover study of single-dose guanfacine in unilateral neglect following stroke. ( Cohen, DL; Dalmaijer, ES; Gorgoraptis, N; Husain, M; Leff, AP; Li, KMS; Malhotra, PA; Parton, AD, 2018) |
| "Thirteen right hemisphere stroke patients with leftward neglect were included in a randomised, double-blind, placebo-controlled proof-of-concept crossover study that examined the effects of a single dose of guanfacine." | 5.27 | Randomised, double-blind, placebo-controlled crossover study of single-dose guanfacine in unilateral neglect following stroke. ( Cohen, DL; Dalmaijer, ES; Gorgoraptis, N; Husain, M; Leff, AP; Li, KMS; Malhotra, PA; Parton, AD, 2018) |
| "Guanfacine may prove to be a useful tool in the treatment of disorders of attention associated with neurological conditions." | 1.37 | Attention deficits following ADEM ameliorated by guanfacine. ( Farmer, SF; Husain, M; Malhotra, P; Singh-Curry, V, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dalmaijer, ES | 1 |
| Li, KMS | 1 |
| Gorgoraptis, N | 1 |
| Leff, AP | 1 |
| Cohen, DL | 1 |
| Parton, AD | 2 |
| Husain, M | 3 |
| Malhotra, PA | 2 |
| Singh-Curry, V | 1 |
| Malhotra, P | 1 |
| Farmer, SF | 1 |
| Greenwood, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Trial of Guanfacine, an Alpha 2 Adrenergic Agonist, for Spatial Neglect and Impaired Vigilance Following Stroke and Focal Brain Damage[NCT00955253] | Phase 2 | 13 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Touchscreen Cancellation: This is a computerised scale for measuring the severity of spatial neglect as described in previous publications (Malhotra et al, Annals of Neurology 2006; Parton et al, Neuroreport 2006). Patients are asked to find and touch targets (which are embedded amongst distractors) on a touchscreen. In the variant of the task employed here, the targets are not marked when touched (Invisible Cancellation).The maximum number of targets that can be found is 64 (Therefore minimum score =0, maximum = 64), which represents normal performance." (NCT00955253)
Timeframe: 5 days
| Intervention | Number of targets found (Mean) | |
|---|---|---|
| Touchscreen Cancellation-Guanfacine | Touchscreen Cancellation-Placebo | |
| All Patients | 31.15 | 26.15 |
1 trial available for guanfacine and Hemisensory Neglect
| Article | Year |
|---|---|
Randomised, double-blind, placebo-controlled crossover study of single-dose guanfacine in unilateral neglect following stroke.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Attention; Cross-Over Studies; Double-Blind Metho | 2018 |
2 other studies available for guanfacine and Hemisensory Neglect
| Article | Year |
|---|---|
Attention deficits following ADEM ameliorated by guanfacine.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Arousal; Attention; Encephalomyelitis, Acute Disseminat | 2011 |
Noradrenergic modulation of space exploration in visual neglect.
Topics: Adrenergic alpha-Agonists; Animals; Attention; Guanfacine; Humans; Neuropsychological Tests; Norepin | 2006 |